Please login to the form below

Not currently logged in
Email:
Password:

Actelion announces results

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year

Half-year financial results for Swiss biopharmaceutical company, Actelion, show net revenue is up 27 per cent compared to the same period last year at CHF 855.2m. The company reported an operating profit of CHF 242.9m compared to CHF 137.2m in H1 2008.

During the six months of 2009, sales of the company's pulmonary arterial hypertension (PAH) drug, Tracleer, reached CHF 739.3m – representing an increase of 23 per cent (in local currencies) compared to the first six months of 2008. The European Commission approved the paediatric dispersible formulation of Tracleer for treatment of PAH in children earlier this month. Sales of Ventavis (also for PAH) increased by 50 per cent in local currencies from CHF 37.9m, in H1 2008 to CHF 61.5m. 

Chief financial officer Andrew Oakley said: "Actelion now expects, unforeseen events excluded, that both total net revenues and cash EBIT [Earnings Before Interest and Tax] - in local currencies - will increase between 16 and 19 per cent for the full year of 2009."

The company reports a pipeline of 10 compounds in clinical development and 25 active projects in drug discovery.

21st July 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics